Search

Your search keyword '"Verdonck, L F"' showing total 381 results
Start Over Author "Verdonck, L F"
381 results on '"Verdonck, L F"'

1. Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years

Author

Cornelissen, J J, Versluis, J, Passweg, J R, van Putten, W L J, Manz, M G, Maertens, J, Beverloo, H B, Valk, P J M, van Marwijk Kooy, M, Wijermans, P W, Schaafsma, M R, Biemond, B J, Vekemans, M-C, Breems, D A, Verdonck, L F, Fey, M F, Jongen-Lavrencic, M, Janssen, J J W M, Huls, G, Kuball, J, Pabst, T, Graux, C, Schouten, H C, Gratwohl, A, Vellenga, E, Ossenkoppele, G, and Löwenberg, B

Published
2015
Full Text
View/download PDF

13. Pre-transplant marital status and hematopoietic cell transplantation outcomes

Author

Tay, J., Beattie, S., Bredeson, C., Brazauskas, R., He, N., Ahmed, I. A., Aljurf, M., Askar, M., Atsuta, Y., Badawy, S., Barata, A., Beitinjaneh, A. M., Bhatt, N. S., Buchbinder, D., Cerny, J., Ciurea, S., D'Souza, A., Dalal, J., Farhadfar, N., Freytes, C. O., Ganguly, S., Gergis, U., Gerull, S., Lazarus, H. M., Hahn, T., Hong, S., Inamoto, Y., Khera, N., Kindwall-Keller, T., Kamble, R. T., Knight, J. M., Koleva, Y. N., Kumar, A., Kwok, J., Murthy, H. S., Olsson, R. F., Angel Diaz-Perez, M., Rizzieri, D., Seo, S., Chhabra, S., Schoemans, H., Schouten, H. C., Steinberg, A., Sullivan, K. M., Szer, J., Szwajcer, D., Ulrickson, M. L., Verdonck, L. F., Wirk, B., Wood, W. A., Yared, J. A., Saber, W., Tay, J., Beattie, S., Bredeson, C., Brazauskas, R., He, N., Ahmed, I. A., Aljurf, M., Askar, M., Atsuta, Y., Badawy, S., Barata, A., Beitinjaneh, A. M., Bhatt, N. S., Buchbinder, D., Cerny, J., Ciurea, S., D'Souza, A., Dalal, J., Farhadfar, N., Freytes, C. O., Ganguly, S., Gergis, U., Gerull, S., Lazarus, H. M., Hahn, T., Hong, S., Inamoto, Y., Khera, N., Kindwall-Keller, T., Kamble, R. T., Knight, J. M., Koleva, Y. N., Kumar, A., Kwok, J., Murthy, H. S., Olsson, R. F., Angel Diaz-Perez, M., Rizzieri, D., Seo, S., Chhabra, S., Schoemans, H., Schouten, H. C., Steinberg, A., Sullivan, K. M., Szer, J., Szwajcer, D., Ulrickson, M. L., Verdonck, L. F., Wirk, B., Wood, W. A., Yared, J. A., and Saber, W.

Abstract

Background Evidence about the impact of marital status before hematopoietic cell transplantation (HCT) on outcomes after HCT is conflicting. Methods We identified patients 40 years of age and older within the Center for International Blood and Marrow Transplant Research registry who underwent HCT between January 2008 and December 2015. Marital status before HCT was declared as one of: married or living with a partner, single (never married), separated or divorced, and widowed. We performed a multivariable analysis to determine the association of marital status with outcomes after HCT. Results We identified 10,226 allogeneic and 5714 autologous HCT cases with, respectively, a median follow-up of 37 months (range: 1-102 months) and 40 months (range: 1-106 months). No association between marital status and overall survival was observed in either the allogeneic (p = 0.58) or autologous (p = 0.17) setting. However, marital status was associated with grades 2-4 acute graft-versus-host disease (GVHD), p < 0.001, and chronic GVHD, p = 0.04. The risk of grades 2-4 acute GVHD was increased in separated compared with married patients [hazard ratio (FIR): 1.13; 95% confidence interval (CI): 1.03 to 1.24], and single patients had a reduced risk of grades 2-4 acute GVHD (FIR: 0.87; 95% CI: 0.77 to 0.98). The risk of chronic GVHD was lower in widowed compared with married patients (FIR: 0.82; 95% CI: 0.67 to 0.99). Conclusions Overall survival after HCT is not influenced by marital status, but associations were evident between marital status and grades 2-4 acute and chronic GVHD. To better appreciate the effects of marital status and social support, future research should consider using validated scales to measure social support and patient and caregiver reports of caregiver commitment, and to assess health-related quality of life together with health care utilization.

Published
2020
Full Text
View/download PDF

17. Pre-Transplant Marital Status and Hematopoietic Cell Transplantation Outcomes

Author

Tay, J., primary, Beattie, S., additional, Bredeson, C., additional, Brazauskas, R., additional, He, N., additional, Ahmed, I. A., additional, Aljurf, M., additional, Askar, M., additional, Atsuta, Y., additional, Badawy, S., additional, Barata, A., additional, Beitinjaneh, A. M., additional, Bhatt, N. S., additional, Buchbinder, D., additional, Cerny, J., additional, Ciurea, S., additional, D’Souza, A., additional, Dalal, J., additional, Farhadfar, N., additional, Freytes, C. O., additional, Ganguly, S., additional, Gergis, U., additional, Gerull, S., additional, Lazarus, H. M., additional, Hahn, T., additional, Hong, S., additional, Inamoto, Y., additional, Khera, N., additional, Kindwall-Keller, T., additional, Kamble, R. T., additional, Knight, J. M., additional, Koleva, Y. N., additional, Kumar, A., additional, Kwok, J., additional, Murthy, H. S., additional, Olsson, R. F., additional, Angel Diaz-Perez, M., additional, Rizzieri, D., additional, Seo, S., additional, Chhabra, S., additional, Schoemans, H., additional, Schouten, H. C., additional, Steinberg, A., additional, Sullivan, K. M., additional, Szer, J., additional, Szwajcer, D., additional, Ulrickson, M. L., additional, Verdonck, L. F., additional, Wirk, B., additional, Wood, W. A., additional, Yared, J. A., additional, and Saber, W., additional

Published
2020
Full Text
View/download PDF

30. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–98 at European Group for Blood and Marrow Transplantation centres

Author

Gahrton, G., Svensson, H., Cavo, M., Apperley, J., Bacigalupo, A., Björkstrand, B., Bladé, J., Cornelissen, J., de Laurenzi, A., Facon, T., Ljungman, P., Michallet, M., Niederwieser, D., Powles, R., Reiffers, J., Russell, N. H., Samson, D., Schaefer, U. W., Schattenberg, A., Tura, S., Verdonck, L. F., Vernant, J. P., Willemze, R., and Volin, L.

Published
2001

39. Autologous Bone Marrow Transplantation in Acute Myeloid Leukemia in First Remission: First Dutch Prospective Study

Author

Löwenberg, B., primary, van Putten, W. L. J., additional, Verdonck, L. F., additional, Dekker, A. W., additional, de Gast, G. C., additional, Willemze, R., additional, Zwaan, F. E., additional, Abels, J., additional, Sonneveld, P., additional, van der Lelie, J., additional, Goudsmit, R., additional, Sizoo, W., additional, and Hagenbeek, A., additional

Published
1990
Full Text
View/download PDF

44. Depletion of T Cells from Bone Marrow Grafts with Soybean Agglutinin and Sheep Red Blood Cells for Prevention of Graft-Versus-Host Disease

Author

Verdonck, L. F., Dekker, A. W., van Heugten, H., van Kempen, M. L., Punt, K., de Gast, G. C., Heimpel, H., editor, Huhn, D., editor, Mueller-Eckhardt, C., editor, Ruhenstroth-Bauer, G., editor, Büchner, T., editor, Schellong, G., editor, Hiddemann, W., editor, Urbanitz, D., editor, and Ritter, J., editor

Published
1987
Full Text
View/download PDF

48. Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years

Author

Cornelissen, J. J., Versluis, J., Passweg, J. R., Van Putten, W. L J, Manz, M. G., Maertens, J., Beverloo, H. B., Valk, P. J M, Van Marwijk Kooy, M., Wijermans, P. W., Schaafsma, M. R., Biemond, B. J., Vekemans, M. C., Breems, D. A., Verdonck, L. F., Fey, M. F., Jongen-Lavrencic, M., Janssen, J. J W M, Huls, G., Kuball, J., Pabst, T., Graux, C., Schouten, H. C., Gratwohl, A., Vellenga, E., Ossenkoppele, G., Löwenberg, B., Cornelissen, J. J., Versluis, J., Passweg, J. R., Van Putten, W. L J, Manz, M. G., Maertens, J., Beverloo, H. B., Valk, P. J M, Van Marwijk Kooy, M., Wijermans, P. W., Schaafsma, M. R., Biemond, B. J., Vekemans, M. C., Breems, D. A., Verdonck, L. F., Fey, M. F., Jongen-Lavrencic, M., Janssen, J. J W M, Huls, G., Kuball, J., Pabst, T., Graux, C., Schouten, H. C., Gratwohl, A., Vellenga, E., Ossenkoppele, G., and Löwenberg, B.

Published
2015

49. Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, UCL - (SLuc) Service d'hématologie, Cornelissen, J J, Versluis, J, Passweg, J R, van Putten, W L J, Manz, M G, Maertens, J, Beverloo, H B, Valk, P J M, van Marwijk Kooy, M, Wijermans, P W, Schaafsma, M R, Biemond, B J, Vekemans, Marie-Christiane, Breems, D A, Verdonck, L F, Fey, M F, Jongen-Lavrencic, M, Janssen, J J W M, Huls, G, Kuball, J, Pabst, T, Graux, Carlos, Schouten, H C, Gratwohl, A, Vellenga, E, Ossenkoppele, G, Löwenberg, B, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, UCL - (SLuc) Service d'hématologie, Cornelissen, J J, Versluis, J, Passweg, J R, van Putten, W L J, Manz, M G, Maertens, J, Beverloo, H B, Valk, P J M, van Marwijk Kooy, M, Wijermans, P W, Schaafsma, M R, Biemond, B J, Vekemans, Marie-Christiane, Breems, D A, Verdonck, L F, Fey, M F, Jongen-Lavrencic, M, Janssen, J J W M, Huls, G, Kuball, J, Pabst, T, Graux, Carlos, Schouten, H C, Gratwohl, A, Vellenga, E, Ossenkoppele, G, and Löwenberg, B

Abstract

The preferred type of post-remission therapy (PRT) in patients with acute myeloid leukemia (AML) in first complete remission (CR1) is a subject of continued debate, especially in patients at higher risk of nonrelapse mortality (NRM), including patients >40 years of age. We report results of a time-dependent multivariable analysis of allogenic hematopoietic stem cell transplantation (alloHSCT) (n=337) versus chemotherapy (n=271) or autologous HSCT (autoHSCT) (n=152) in 760 patients aged 40-60 years with AML in CR1. Patients receiving alloHSCT showed improved overall survival (OS) as compared with chemotherapy (respectively, 57±3% vs 40±3% at 5 years, P<0.001). Comparable OS was observed following alloHSCT and autoHSCT in patients with intermediate-risk AML (60±4 vs 54±5%). However, alloHSCT was associated with less relapse (hazard ratio (HR) 0.51, P<0.001) and better relapse-free survival (RFS) (HR 0.74, P=0.029) as compared with autoHSCT in intermediate-risk AMLs. AlloHSCT was applied following myeloablative conditioning (n=157) or reduced intensity conditioning (n=180), resulting in less NRM, but comparable outcome with respect to OS, RFS and relapse. Collectively, these results show that alloHSCT is to be preferred over chemotherapy as PRT in patients with intermediate- and poor-risk AML aged 40-60 years, whereas autoHSCT remains a treatment option to be considered in patients with intermediate-risk AML.Leukemia advance online publication, 23 December 2014; doi:10.1038/leu.2014.332.

Published
2015

50. Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years

Author

HAG Diabetes, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, MS Hematologie, Infection & Immunity, Cancer, Cornelissen, J. J., Versluis, J., Passweg, J. R., Van Putten, W. L J, Manz, M. G., Maertens, J., Beverloo, H. B., Valk, P. J M, Van Marwijk Kooy, M., Wijermans, P. W., Schaafsma, M. R., Biemond, B. J., Vekemans, M. C., Breems, D. A., Verdonck, L. F., Fey, M. F., Jongen-Lavrencic, M., Janssen, J. J W M, Huls, G., Kuball, J., Pabst, T., Graux, C., Schouten, H. C., Gratwohl, A., Vellenga, E., Ossenkoppele, G., Löwenberg, B., HAG Diabetes, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, MS Hematologie, Infection & Immunity, Cancer, Cornelissen, J. J., Versluis, J., Passweg, J. R., Van Putten, W. L J, Manz, M. G., Maertens, J., Beverloo, H. B., Valk, P. J M, Van Marwijk Kooy, M., Wijermans, P. W., Schaafsma, M. R., Biemond, B. J., Vekemans, M. C., Breems, D. A., Verdonck, L. F., Fey, M. F., Jongen-Lavrencic, M., Janssen, J. J W M, Huls, G., Kuball, J., Pabst, T., Graux, C., Schouten, H. C., Gratwohl, A., Vellenga, E., Ossenkoppele, G., and Löwenberg, B.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results